CAR-T: A patient’s cell therapy success story

Clinical trials of (CAR) T-cell therapies can present unprecedented enrolment challenges. How can we encourage participation in these trials? Doug Olson, one of the first CAR-T patients treated on a clinical trial, shares his experiences with Alberto Grignolo, Parexel's Corporate Vice President, Regulatory Consulting Services.

Visit www.parexel.com/neverstop to learn how our Regulatory & Access experts can help apply patient insights to your strategy.

Previous Flipbook
Dosing strategies for gene therapies
Dosing strategies for gene therapies

In this article, our gene therapy experts at Health Advances, Parexel’s commercial strategy group, outline ...

Next Article
The Parexel Podcast | Episode 12: ASCO20 Debrief: The latest in cell and gene therapy
The Parexel Podcast | Episode 12: ASCO20 Debrief: The latest in cell and gene therapy

In 2020, ASCO went virtual for the first time. While the format was different, one thing was clear: despite...

×

Let's start a conversation...

First Name
Last Name
Job Title
Company Name
Country
Therapeutic Area Interest - optional
Tell us how we can help
Thank you! We'll be in touch soon.
Error - something went wrong!